VRTX Insider Trading
VERTEX PHARMACEUTICALS INC / MA | Pharmaceutical Preparations
Comprehensive Trading Performance Summary
The investment history of corporate insiders at VERTEX PHARMACEUTICALS INC / MA provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Pharmaceutical Preparations sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-03 20:53 | 2026-04-01 | Liu Joy | Officer - EVP and Chief Legal Officer | SELL | $449.17 | 978 | $439,288 | 21,833 | -4.3% |
| 2026-03-31 20:10 | 2026-03-27 | Bozic Carmen | Officer - EVP and CMO | SELL | $450.95 | 2,329 | $1,050,263 | 33,076 | -6.6% |
| 2026-03-17 20:04 | 2026-03-13 | Bozic Carmen | Officer - EVP and CMO | SELL | $481.79 | 2,329 | $1,122,089 | 35,405 | -6.2% |
| 2026-03-13 20:11 | 2026-03-11 | McKechnie Duncan | Officer - EVP, Chief Commercial Officer | SELL | $498.42 | 2,633 | $1,312,340 | 12,489 | -17.4% |
| 2026-03-07 00:05 | 2026-03-04 | McKechnie Duncan | Officer - EVP, Chief Commercial Officer | SELL | $475.30 | 2,437 | $1,158,306 | 15,122 | -13.9% |
| 2026-03-05 00:21 | 2026-03-02 | Liu Joy | Officer - EVP and Chief Legal Officer | SELL | $495.96 | 892 | $442,396 | 22,811 | -3.8% |
| 2026-03-04 00:34 | 2026-02-27 | Kewalramani Reshma | Director, Officer - CEO & President | SELL | $493.47 | 40,000 | $19,738,856 | 98,278 | -28.9% |
| 2026-03-04 00:25 | 2026-02-27 | Bozic Carmen | Officer - EVP and CMO | SELL | $480.31 | 2,329 | $1,118,642 | 37,734 | -5.8% |
| 2026-03-03 00:10 | 2026-02-26 | Ambrose Kristen | Officer - SVP & Chief Accounting Officer | SELL | $483.36 | 357 | $172,560 | 6,624 | -5.1% |
| 2026-02-27 02:55 | 2026-02-25 | Tatsis Ourania | Officer - EVP, Chief Reg. & Quality Off. | SELL | $486.35 | 260 | $126,451 | 46,763 | -0.6% |
| 2026-02-27 02:48 | 2026-02-25 | McKechnie Duncan | Officer - EVP, Chief Commercial Officer | SELL | $487.65 | 4,910 | $2,394,365 | 17,559 | -21.9% |
| 2026-02-27 02:50 | 2026-02-25 | Sachdev Amit | Officer - EVP Chief Patient & Ext Af Off | SELL | $486.35 | 1,846 | $897,802 | 55,570 | -3.2% |
| 2026-02-27 01:56 | 2026-02-25 | Ambrose Kristen | Officer - SVP & Chief Accounting Officer | SELL | $486.35 | 223 | $108,456 | 6,981 | -3.1% |
| 2026-02-27 02:00 | 2026-02-25 | Atkinson Edward Morrow III | Officer - EVP, Chief Technical Ops. Off. | SELL | $486.35 | 668 | $324,882 | 18,432 | -3.5% |
| 2026-02-27 02:01 | 2026-02-25 | Biller Jonathan | Officer - EVP and Chief Legal Officer | SELL | $486.35 | 945 | $459,601 | 13,659 | -6.5% |
| 2026-02-27 02:06 | 2026-02-25 | Bunnage Mark E. | Officer - EVP, Chief Scientific Officer | SELL | $486.35 | 620 | $301,537 | 7,284 | -7.8% |
| 2026-02-24 00:21 | 2026-02-19 | Sachdev Amit | Officer - EVP Chief Patient & Ext Af Off | OPT+S | $468.83 | 58,613 | $27,479,586 | 58,934 | 0.0% |
| 2026-02-20 00:12 | 2026-02-17 | Bunnage Mark E. | Officer - EVP, Chief Scientific Officer | SELL | $484.31 | 3,619 | $1,752,704 | 8,486 | -29.9% |
| 2026-02-20 00:06 | 2026-02-17 | Atkinson Edward Morrow III | Officer - EVP, Chief Technical Ops. Off. | SELL | $484.93 | 2,848 | $1,381,090 | 20,727 | -12.1% |
| 2026-02-20 00:03 | 2026-02-17 | Ambrose Kristen | Officer - SVP & Chief Accounting Officer | SELL | $484.87 | 2,195 | $1,064,297 | 7,750 | -22.1% |
| 2026-02-20 00:08 | 2026-02-17 | Biller Jonathan | Officer - EVP and Chief Legal Officer | SELL | $484.18 | 3,720 | $1,801,161 | 15,748 | -19.1% |
| 2026-02-20 00:28 | 2026-02-17 | Tatsis Ourania | Officer - EVP, Chief Reg. & Quality Off. | SELL | $483.52 | 977 | $472,395 | 48,650 | -2.0% |
| 2026-02-19 00:26 | 2026-02-13 | Biller Jonathan | Officer - EVP and Chief Legal Officer | SELL | $499.00 | 988 | $493,012 | 16,838 | -5.5% |
| 2026-02-19 00:23 | 2026-02-13 | Bhatia Sangeeta N. | Director | SELL | $500.00 | 266 | $133,000 | 4,299 | -5.8% |
| 2026-02-19 00:43 | 2026-02-13 | Tatsis Ourania | Officer - EVP, Chief Reg. & Quality Off. | SELL | $499.99 | 1,500 | $749,985 | 46,132 | -3.1% |
| 2026-02-13 01:08 | 2026-02-11 | Tatsis Ourania | Officer - EVP, Chief Reg. & Quality Off. | SELL | $460.43 | 466 | $214,560 | 51,436 | -0.9% |
| 2026-02-13 00:52 | 2026-02-11 | Biller Jonathan | Officer - EVP and Chief Legal Officer | SELL | $460.43 | 1,925 | $886,328 | 20,819 | -8.5% |
| 2026-02-13 00:56 | 2026-02-11 | Bunnage Mark E. | Officer - EVP, Chief Scientific Officer | SELL | $460.43 | 2,021 | $930,529 | 12,914 | -13.5% |
| 2026-02-13 00:47 | 2026-02-11 | Ambrose Kristen | Officer - SVP & Chief Accounting Officer | SELL | $460.43 | 1,376 | $633,552 | 10,127 | -12.0% |
| 2026-02-13 00:50 | 2026-02-11 | Atkinson Edward Morrow III | Officer - EVP, Chief Technical Ops. Off. | SELL | $460.43 | 1,751 | $806,213 | 22,046 | -7.4% |
| 2026-01-10 00:05 | 2026-01-07 | Tatsis Ourania | Officer - EVP, Chief Reg. & Quality Off. | SELL | $474.99 | 4,500 | $2,137,455 | 42,293 | -9.6% |
| 2026-01-09 00:04 | 2026-01-06 | WAGNER CHARLES F JR | Officer - EVP, CO & FO | OPT+S | $461.00 | 9,532 | $4,394,252 | 37,725 | 0.0% |
| 2025-12-06 00:12 | 2025-12-03 | Tatsis Ourania | Officer - EVP, Chief Reg. & Quality Off. | SELL | $449.99 | 4,500 | $2,024,955 | 46,793 | -8.8% |
| 2025-12-06 00:06 | 2025-12-03 | Biller Jonathan | Officer - EVP and Chief Legal Officer | SELL | $449.00 | 347 | $155,803 | 15,306 | -2.2% |
| 2025-12-06 00:10 | 2025-12-03 | LEIDEN JEFFREY M | Director, Officer - Executive Chairman | OPT+S | $449.20 | 63,781 | $28,650,336 | 24,026 | 0.0% |
| 2025-12-06 00:16 | 2025-12-03 | WAGNER CHARLES F JR | Officer - EVP, CO & FO | SELL | $456.00 | 14,000 | $6,384,000 | 37,725 | -27.1% |
| 2025-11-20 00:06 | 2025-11-17 | Atkinson Edward Morrow III | Officer - EVP, Chief Technical Ops. Off. | SELL | $434.58 | 2,500 | $1,086,450 | 16,852 | -12.9% |
| 2025-11-18 00:12 | 2025-11-13 | LEIDEN JEFFREY M | Director, Officer - Executive Chairman | OPT+S | $440.60 | 73,292 | $32,292,323 | 24,026 | 0.0% |
| 2025-10-03 23:07 | 2025-10-02 | Biller Jonathan | Officer - EVP and Chief Legal Officer | SELL | $404.21 | 694 | $280,522 | 15,653 | -4.2% |
| 2025-08-29 23:02 | 2025-08-27 | Bhatia Sangeeta N. | Director | SELL | $386.69 | 266 | $102,860 | 4,565 | -5.5% |
| 2025-08-07 23:23 | 2025-08-06 | Kewalramani Reshma | Director, Officer - CEO & President | BUY | $389.58 | 10,000 | $3,895,768 | 115,968 | +9.4% |
| 2025-08-07 23:19 | 2025-08-06 | SACHS BRUCE I | Director | BUY | $389.68 | 5,000 | $1,948,416 | 45,000 | +12.5% |
| 2025-05-20 00:07 | 2025-05-15 | ALTSHULER DAVID | Officer - EVP, Chief Scientific Officer | SELL | $424.69 | 52 | $22,084 | 23,281 | -0.2% |
| 2025-05-05 23:14 | 2025-05-02 | Bhatia Sangeeta N. | Director | SELL | $505.86 | 400 | $202,344 | 4,831 | -7.6% |
| 2025-03-17 23:09 | 2025-03-13 | ALTSHULER DAVID | Officer - EVP, Chief Scientific Officer | SELL | $510.00 | 3,231 | $1,647,810 | 23,281 | -12.2% |
| 2025-03-12 23:10 | 2025-03-10 | Tatsis Ourania | Officer - EVP, Chief Reg. & Quality Off. | SELL | $499.99 | 3,242 | $1,620,968 | 51,239 | -6.0% |
| 2025-03-12 23:08 | 2025-03-10 | ALTSHULER DAVID | Officer - EVP, Chief Scientific Officer | SELL | $500.00 | 3,231 | $1,615,500 | 26,512 | -10.9% |
| 2025-03-12 23:11 | 2025-03-10 | WAGNER CHARLES F JR | Officer - EVP & Chief Financial Officer | SELL | $500.00 | 3,298 | $1,649,000 | 51,671 | -6.0% |
| 2025-03-07 00:08 | 2025-03-04 | Tatsis Ourania | Officer - EVP, Chief Reg. & Quality Off. | SELL | $485.49 | 4,058 | $1,970,118 | 54,481 | -6.9% |
| 2025-03-06 00:08 | 2025-03-03 | ALTSHULER DAVID | Officer - EVP, Chief Scientific Officer | SELL | $490.00 | 3,231 | $1,583,190 | 29,743 | -9.8% |
How to Interpret $VRTX Trades
Not every insider transaction in VERTEX PHARMACEUTICALS INC / MA is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $VRTX shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for VRTX
Insider activity data for VERTEX PHARMACEUTICALS INC / MA is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $VRTX, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.